INOVIQ’s CAR-Exosomes Achieve Up to 90% Tumour Kill in Ovarian Cancer Cells
2 min read
8:46am on Thursday 25th of June, 2026 AEST ~8am, 25th June, 26
Popular on LinkedIn
INOVIQ Limited’s CAR-exosome platform demonstrated potent tumour-killing activity in ovarian cancer cell lines, eliminating up to 90% of cancer cells within 48 hours and reinforcing its potential against hard-to-treat solid tumours.
- CAR-exosomes killed over 90% of ovarian cancer cells in vitro
- Effective against aggressive and drug-resistant ovarian cancer lines
- Platform shows promise across multiple solid tumours including TNBC and NSCLC
- Manufacturing readiness progressing with GMP cell sourcing and CDMO selection
- New dual-action CAR-exosome data expected in Q4 2026
Strong In Vitro Tumour Killing in Ovarian Cancer Models
INOVIQ Limited (ASX:IIQ) has unveiled compelling in vitro proof-of-concept data showing its CAR-exosome therapeutics can eliminate up to 90% of ovarian cancer cells within 48 hours. The study targeted three ovarian cancer cell lines, including OVCAR-3 and Caov-3, where CA125- and EGFR-targeting CAR-exosomes achieved rapid and effective tumour cell killing. Even the notoriously aggressive and treatment-resistant SK-OV-3 line saw approximately 50% cell death, underscoring the platform’s potential against challenging tumour types.
Expanding the Reach Beyond Ovarian Cancer
This latest data builds on INOVIQ’s previous demonstrations of CAR-exosome activity in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), positioning the technology as a versatile off-the-shelf, cell-free therapeutic approach for multiple hard-to-treat solid tumours. The company’s Chief Scientific Officer, Dr Rebecca Lim, highlighted the significance of showing tumour-killing activity across diverse cancer models and different tumour-targeting strategies, reinforcing the platform’s broad applicability.
Manufacturing and Development Milestones in Focus
INOVIQ is advancing manufacturing readiness by sourcing GMP-compliant cells and selecting contract development and manufacturing organisations (CDMOs) to scale production. The company is also optimising next-generation dual-action CAR-exosomes designed to target tumour cells and modulate the tumour microenvironment. These efforts aim to support progression toward first-in-human studies planned for 2028, marking a critical step from preclinical promise to clinical evaluation.
Strategic Integration with Diagnostic Advances
CEO Dr Leearne Hinch emphasised the synergy between INOVIQ’s CAR-exosome therapeutics and its EXO-OC™ blood test for ovarian cancer detection. This integrated approach seeks to combine earlier diagnosis with more effective treatment options, potentially improving patient outcomes in a cancer type often diagnosed late and resistant to current therapies. The company expects new in vitro tumour-killing data from dual-action CAR-exosomes in TNBC cells by Q4 2026, which could further validate and enhance its therapeutic pipeline.
Bottom Line?
INOVIQ’s CAR-exosome platform shows promising preclinical potency against ovarian cancer, but clinical validation and manufacturing scale-up remain key hurdles before therapeutic impact can be realised.
Questions in the middle?
- Will the dual-action CAR-exosomes deliver enhanced tumour killing in upcoming TNBC data?
- How will INOVIQ navigate manufacturing scale-up challenges to meet clinical trial demands?
- What regulatory and safety profiles will emerge as the platform moves toward first-in-human studies?
